Română

Articole ISI

2018

Comment on “Intravitreal dexamethasone implants for diabetic macular edema”

December 2018, Volume 11, Issue 12, p. 2029-2032
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: IJO - International Journal of Ophthalmology

Anti-VEGF Treatment for Diabetic Macular Edema in a Real-World Clinical Setting

December 2018, Volume 196, p. 208–209
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: AJO - American Journal of Ophthalmology

Comment on “Assessment of the long-term visual and anatomical outcomes of ranibizumab to treat neovascular age-related macular degeneration”

November 2018, Volume 11, Issue 11, p. 1884-1886
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: IJO - International Journal of Ophthalmology

Clinical Features of Central Serous Chorioretinopathy With Type 1 Choroidal Neovascularization

November 2018, Volume 195, p. 245–246
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: AJO - American Journal of Ophthalmology

Safety and long-term efficacy of repeated dexamethasone intravitreal implant for the treatment of cystoid macular edema secondary to retinal vein occlusion with and without a switch to anti-VEGF agents: a 3-year experience

November 2018, Volume 256, Issue 11, pp. 2269–2270
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Graefe’s Archive for Clinical and Experimental Ophthalmology

Real-world outcomes of anti-vascular endothelial growth factor therapy in diabetic macular edema in the united states

October 2018, Volume 10, Issue 10, pp.74665-74666
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: International Journal of Current Research

Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy

October 2018, Volume 10, Issue 10, pp.74701-74702
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: International Journal of Current Research

Re: Li et al.: Long-term Assessment of Macular Atrophy in Patients with Age-Related Macular Degeneration Receiving Anti-Vascular Endothelial Growth Factor

October 2018, Volume 2, Issue 10, p. e13-e14
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Ophthalmology Retina

Guidelines on diabetic eye care. the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings

September 2018, Volume 8, Issue 9, pp. 22645-22646
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: International Journal of Development Research

Vision Outcomes Following Anti–Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice

September 2018, Volume 193, p. 253–254
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: AJO - American Journal of Ophthalmology

Comment on “Management strategies in malignant glaucoma secondary to antiglaucoma surgery”

August 2018, Volume 11, Issue 8, p. 1433-1434
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: IJO - International Journal of Ophthalmology

Correspondence

August 2018, Volume 38, Issue 8, p. e69–e71
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Retina - The Journal of Retinal and Vitreous Diseases

What We Have Learned From the Ocular Hypertension Treatment Study

August 2018, Volume 192, p. 248–249
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: AJO - American Journal of Ophthalmology

The fate of eyes with wet AMD beyond 4 years of anti-VEGF therapy

August 2018, Volume 256, Issue 8, pp. 1551–1552
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Graefe’s Archive for Clinical and Experimental Ophthalmology

Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy

July, 2018, Volume 10, Issue 7, pp. 71192-71193
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: International Journal of Current Research

Sustained benefits from ranibizumab for central retinal vein occlusion with macular edema: 24-month results of the crystal study

July 2018, Volume 10, Issue 7, pp. 71828-71829
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: International Journal of Current Research

Ocular hypertension in patients with central/hemicentral retinal vein occlusions: cumulative prevalence and management

July 2018, Volume 11, Issue 7, pp. 1173-1178
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: IJO - International Journal of Ophthalmology

Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success

July 2018, Volume 256, Issue 7, pp. 1353–1354
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Graefe’s Archive for Clinical and Experimental Ophthalmology

Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study

June 2018, Volume 256, Issue 6, pp. 1209–1210
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Graefe’s Archive for Clinical and Experimental Ophthalmology

Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment

May 2018, Volume 256, Issue 5, pp. 1035–1037
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Graefe’s Archive for Clinical and Experimental Ophthalmology

Outcomes of Patients Initially Treated with Intravitreal Bevacizumab for Central Retinal Vein Occlusion: Long-Term Follow-Up

May 2018, Volume 33, Issue 3, p.318-319
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Seminars in Ophthalmology

Aflibercept for patients with neovascular age-related macular degeneration in routine clinical practice in Germany. Twelve-month outcomes of Perseus

April 2018, Volume 10, Issue 4, pp. 68602-68603
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: International Journal of Current Research

Letter to the Editor: Ranibizumab 0.3 mg for Persistent Diabetic Macular Edema After Recent, Frequent, and Chronic Bevacizumab: The ROTATE Trial

March 2018, Volume 49, Issue 3, p. 160
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: OSLI Retina - Ophthalmic Surgery, Lasers & Imaging Retina

Re: Khurana et al.: Aflibercept for Previously Treated Macular Edema Associated with Central Retinal Vein Occlusions: 1-Year Results of the NEWTON Study (Ophthalmol Retina. 2017)

March 2018, Volume 2, Issue 3, p. e5–e6
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Ophthalmology Retina

Inner nuclear layer cystoid spaces are a poor prognostic factor in typical age-related macular degeneration and polypoidal choroidal vasculopathy

March 2018, Volume 256, Issue 3, pp. 627–629
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Graefe’s Archive for Clinical and Experimental Ophthalmology

Early Response to Intravitreal Dexamethasone Implant Therapy in Diabetic Macular Edema May Predict Visual Outcome

February 2018, Volume 186, p.164–165
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: AJO - American Journal of Ophthalmology

Comments to: Restoration of photoreceptors in eyes with diabetic macular edema.

January 2018, Volume 28, Issue 1, pp. 132-133
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: EJO - European Journal of Ophthalmology

Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy

January 2018, Volume 256, Issue 1, pp. 233–235
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Graefe’s Archive for Clinical and Experimental Ophthalmology

Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy

January 2018, Volume 256, Issue 1, pp. 221–223
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Graefe’s Archive for Clinical and Experimental Ophthalmology

2017

Disorganization of the Retinal Inner Layers as a Predictor of Visual Acuity in Eyes With Macular Edema Secondary to Vein Occlusion

December 2017, Volume 184, p.190–191
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: AJO - American Journal of Ophthalmology

Comments to: Real-world outcomes of anti-VEGF treatment for retinal vein occlusion in Portugal

Nov-Dec 2017, Volume 27, Issue 6, pp. 627 - 800, e175 - e195
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: EJO - European Journal of Ophthalmology

Correspondence

November 2017 - Volume 37 - Issue 11 - p e139–e141
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Retina - The Journal of Retinal and Vitreous Diseases

Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-Related Macular Degeneration: A Prospective Clinical Trial

October 2017, Volume 182, p.204–205
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: AJO - American Journal of Ophthalmology

Ranibizumab versus dexamethasone implant for central retinal vein occlusion: the Ranidex study

October 2017, Volume 255, Issue 10, pp. 2073–2075
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Graefe’s Archive for Clinical and Experimental Ophthalmology

High-frequency aflibercept injections in persistent neovascular age-related macular degeneration

October 2017, Volume 255, Issue 10, pp. 2067–2068
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Graefe’s Archive for Clinical and Experimental Ophthalmology

Comment on “Predictors of short-term outcomes related to central subfield foveal thickness after intravitreal bevacizumab for macular edema due to central retinal vein occlusion”

September 2017, Volume 10, Issue 9, p.1481-1482
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: IJO - International Journal of Ophthalmology

Correspondence

September 2017, Volume 37, Issue 9, p.e108–e110
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Retina - The Journal of Retinal and Vitreous Diseases

Comments to: Visual and anatomic outcomes after conversion to aflibercept in neovascular age-related macular degeneration: 12-month results

Jul-Aug 2017, Volume 27, Issue 4, pp. 387 - 512, e129 - e135
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: EJO - European Journal of Ophthalmology

Letter to the Editor: Aflibercept For Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab And/Or Bevacizumab May Further Improve Macular Thickness

July 2017, Volume 48, Issue 7, p.528-529
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: OSLI Retina - Ophthalmic Surgery, Lasers & Imaging Retina

Treatment patterns of ranibizumab intravitreal injection and dexamethasone intravitreal implant for retinal vein occlusion in the USA

July 2017, Volume 31, Issue 7, p.1112-1113
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Eye - The Scientific Journal of the Royal College of Ophthalmologists

Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema

July 2017, Volume 255, Issue 7, pp. 1451–1452
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Graefe’s Archive for Clinical and Experimental Ophthalmology

Ranibizumab versus aflibercept for macular edema due to central retinal vein occlusion: 18-month results in real-life data

July 2017, Volume 255, Issue 7, pp. 1455–1457
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Graefe’s Archive for Clinical and Experimental Ophthalmology

Correspondence

Jun 2017, Volume 37, Issue 6, p. e84–e86
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Retina - The Journal of Retinal and Vitreous Diseases

Correspondence

Jun 2017, Volume 37, Issue 6, p. e78–e79
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Retina - The Journal of Retinal and Vitreous Diseases

Comments to: Ranibizumab for persistent diabetic macular edema after bevacizumab treatment

May-Jun 2017, Volume 27, Issue 3, pp. 253 - 386, e99 - e128
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: EJO - European Journal of Ophthalmology

Comments to: Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization

May-Jun 2017, Volume 27, Issue 3, pp. 253 - 386, e99 - e128
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: EJO - European Journal of Ophthalmology

Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study

May 2017, Volume 177, p.235–236
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: AJO - American Journal of Ophthalmology

Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion

May 2017, Volume 255, Issue 5, pp. 1043–1044
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Graefe’s Archive for Clinical and Experimental Ophthalmology

Early response to ranibizumab predictive of functional outcome after dexamethasone for unresponsive diabetic macular oedema

Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: BJO - British Journal of Ophthalmology

Letter to the Editor: Short-Term Outcomes of Aflibercept Therapy for Diabetic Macular Edema in Patients With Incomplete Response to Ranibizumab and/or Bevacizumab

April 2017, Volume 48, Issue 4, p.280
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: OSLI Retina - Ophthalmic Surgery, Lasers & Imaging Retina

Baseline Choroidal Thickness as a Predictor for Treatment Outcomes in Central Retinal Vein Occlusion

April 2017, Volume 176, p.257–258
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: AJO - American Journal of Ophthalmology

Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy

Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: BJO - British Journal of Ophthalmology

Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion

February 2017, Volume 52, Issue 1, p.137
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Canadian Journal of Ophthalmology

Correspondence - Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option

February 2017, Volume 31, Issue 2, p.342
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Eye - The Scientific Journal of the Royal College of Ophthalmologists

Real-World Outcomes of Ranibizumab Treatment for Diabetic Macular Edema in a United Kingdom National Health Service Setting

February 2017, Volume 174, p.175–176
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: AJO - American Journal of Ophthalmology

Dexamethasone intravitreal implant in retinal vein occlusion:real-life data from a prospective, multicenter clinical trial

February 2017, Volume 255, Issue 2, pp. 427–428
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Graefe’s Archive for Clinical and Experimental Ophthalmology

Comparison of Time to Retreatment and Visual Function Between Ranibizumab and Aflibercept in Age-Related Macular Degeneration

February 2017, Volume 174, p.181–182
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: AJO - American Journal of Ophthalmology

Long-term Outcomes of Aflibercept Treatment for Neovascular Age-related Macular Degeneration in a Clinical Setting

February 2017, Volume 174, p.185–186
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: AJO - American Journal of Ophthalmology

Morphological and functional changes in recalcitrant diabetic macular oedema after intravitreal dexamethasone implant

Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: BJO - British Journal of Ophthalmology

Correspondence - Aflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy

January 2017, Volume 31, Issue 1, p.162
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Eye - The Scientific Journal of the Royal College of Ophthalmologists

Two-year, prospective, multicenter study of the use of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in the clinical setting in France

January 2017, Volume 255, Issue 1, pp. 211–212
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Graefe’s Archive for Clinical and Experimental Ophthalmology

Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration

January 2017, Volume 173, p.145–146
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: AJO - American Journal of Ophthalmology

2016

Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex) in its treatment

December 2016, Volume 254, Issue 12, pp. 2477–2478
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Graefe’s Archive for Clinical and Experimental Ophthalmology

Comments to: Long-term efficacy and safety of intravitreal dexamethasone implant for the treatment of diabetic macular edema

Nov-Dec 2016, Volume 26, Issue 6, p. e145-e173
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: EJO - European Journal of Ophthalmology

Comment on: "Combination of peripheral laser photocoagulation with intravitreal bevacizumab in naive eyes with macular edema secondary to CRVO: prospective randomized study"

November 2016, Volume 30, Issue 11, p.1520-1521
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Eye - The Scientific Journal of the Royal College of Ophthalmologists

Correspondence

November 2016, Volume 36, p.e112–e113
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Retina - The Journal of Retinal and Vitreous Diseases

Impact of initial visual acuity on anti-VEGF treatment outcomes in patients with macular oedema secondary to retinal vein occlusions in routine clinical practice

Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: BJO - British Journal of Ophthalmology

Correspondence - Comment on: "Central retinal vein occlusion: modifying current treatment protocols"

October 2016, Volume 30, Issue 10, p.1395-1396
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Eye - The Scientific Journal of the Royal College of Ophthalmologists

Pro-permeability Factors in Diabetic Macular Edema; The Diabetic Macular Edema Treated With Ozurdex Trial

October 2016, Volume 170, p.244–245
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: AJO - American Journal of Ophthalmology

Anatomical effects of dexamethasone intravitreal implant in diabetic macular oedema: a pooled analysis of 3-year phase lll trials

Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: BJO - British Journal of Ophthalmology

Correspondence

August 2016, Volume 36, Issue 8, p.e83–e84
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Retina - The Journal of Retinal and Vitreous Diseases

Changing from pro re nata treatment regimen to a treat and extend regimen with ranibizumab in neovascular age-related macular degeneration

Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: BJO - British Journal of Ophthalmology

Comments to: "Response to bevacizumab after treatment with aflibercept in eyes with neovascular AMD"

Sep-Oct 2016, Volume 26, Issue 5, p. e138-e138
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: EJO - European Journal of Ophthalmology

Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy

Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: BJO - British Journal of Ophthalmology

Intravitreal bevacizumab for diabetic macular edema: 5-year results of the Pan-American collaborative retina study group

Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: BJO - British Journal of Ophthalmology

Clinical Efficacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study

September 2016, Volume 169, p.291–292
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: AJO - American Journal of Ophthalmology

Correspondence - Comment on: "Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab"

June 2016, Volume 30, Issue 6, p.896-897
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Eye - The Scientific Journal of the Royal College of Ophthalmologists

Effects of switching from ranibizumab to aflibercept in eyes with exudative age-related macular degeneration

Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: BJO - British Journal of Ophthalmology

Conversion to Aflibercept After Prior Anti-VEGF Therapy for Persistent Diabetic Macular Edema

August 2016, Volume 168, p.290–291
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: AJO - American Journal of Ophthalmology

Bevacizumab treatment of macular edema in CRVO and BRVO: long-term follow-up (BERVOLT study: bevacizumab for RVO long-term follow-up)

May 2016, Volume 254, Issue 5, p.1023–1024
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Graefe’s Archive for Clinical and Experimental Ophthalmology

Correspondence - Comment on: "Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab"

May 2016, Volume 30, Issue 5, p.766
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Eye - The Scientific Journal of the Royal College of Ophthalmologists

Injection scheme for intravitreal bevacizumab therapy for macular oedema due to central retinal vein occlusion: results of a multicenter study

February 2016, Volume 94, Issue 1, p.e80–e81
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Acta Ophthalmologica

Correspondence

February 2016, Volume 36, Issue 2, p.e9–e10
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Retina - The Journal of Retinal and Vitreous Diseases

Pro-permeability Factors After Dexamethasone Implant in Retinal Vein Occlusion; The Ozurdex for Retinal Vein Occlusion (ORVO) Study

January 2016, Volume 161, p.215–216
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: AJO - American Journal of Ophthalmology

2015

Correspondence - Comment on: "The Royal College of Ophthalmologists Guidelines on retinal vein occlusions: executive summary"

December 2015, Volume 29, Issue 12, p.1631-1632
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Eye - The Scientific Journal of the Royal College of Ophthalmologists

Letter to the Editor: "Treat-and-Extend Intravitreal Bevacizumab for Branch Retinal Vein Occlusion"

November - December 2015, Volume 46, Issue 10, p.994
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: OSLI Retina - Ophthalmic Surgery, Lasers & Imaging Retina

Ophthalmic Technology Assessment: therapies for macular edema associated with central retinal vein occlusion: a report by the American Academy of Ophthalmology

November 2015, Volume 122, Issue 11, p.e65–e66
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Ophthalmology

Correspondence

October 2015, Volume 35, Issue 10, p.e59–e61
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Retina - The Journal of Retinal and Vitreous Diseases

Decreasing medication use in patients with ocular hypertension

Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: BJO - British Journal of Ophthalmology

Correspondence - Comment on: "Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA"

Dan Călugăru, Mihai Călugăru
August 2015, Volume 29, Issue 8, p.1113
Source: Eye - The Scientific Journal of the Royal College of Ophthalmologists

Inconclusive treatment recommendations with ranibizumab in retinal vein occlusion by an expert panel

Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: BJO - British Journal of Ophthalmology

Intravitreal Aflibercept for Macular Edema Secondary to Central Retinal Vein Occlusion: 18-Month Results of the Phase 3 GALILEO Study

March 2015, Volume 159, Issue 3, p.607–608
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: AJO - American Journal of Ophthalmology

2014

Intravitreal Bevacizumab in Acute Central/Hemicentral Retinal Vein Occlusions: Three-Year Results of a Prospective Clinical Study

October 2014, Volume 31, Issue 2, p.78-86
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Journal of Ocular Pharmacology and Therapeutics

2013

Prevention of Neovascular Glaucoma

July 2013, Volume 120, Issue 7, p.1507–1508
Dan Călugăru, Mihai Călugăru
University of Medicine Cluj-Napoca, Romania
Source: Ophthalmology
Copyright OcuCenter © 2014-2018. Toate drepturile rezervate.
Cluj-Napoca, Cluj,
Str. Victor Babeș nr.25,
Tel. 0756 100 387 și 0744 602 559
Borşa, Maramureş
Str. Libertatii nr.8A et.1
Tel. 0755 975 897 şi 0744 602 559